HIStalk Interviews Jason Rose, CEO, Clearsense – HIStalk
Jason Rose is CEO of Clearsense.
Tell me about yourself and the company.
I’m Jason Rose, the CEO of Clearsense. I’ve been here about a year. I’ve got 30 years in healthcare technology….
Jason Rose is CEO of Clearsense.
Tell me about yourself and the company.
I’m Jason Rose, the CEO of Clearsense. I’ve been here about a year. I’ve got 30 years in healthcare technology….
Top News
AI-powered cancer drug discovery startup Manas AI launches with a $25 million seed funding round.
The co-founders are LinkedIn co-founder and venture capitalist Reid Hoffman and oncologist-author Siddhartha Mukherjee, DPhil, MD, who wrote Pulitzer…
Several people have reached out this week to try to schedule meetings with me at ViVE, which is coming up next month in Nashville. As much as I would like a good excuse to…
Continue ReadingSocial Care Data: The Key to Unlocking Community HealthBy Carla Nelson
Carla Nelson, MBA is senior director of healthcare polity at Findhelp.
Rising healthcare costs in the US demand innovative solutions, and social…
Continue ReadingTop News
UnitedHealth Group increases its estimate of individuals impacted by a February 2024 ransomware attack on its Change Healthcare division from 100 million to 190 million, affecting nearly half of all Americans.
The company…
Top News
VA secretary nominee Doug Collins tells the Senate Veterans’ Affairs Committee that he will review the VA’s Oracle Health implementation with a fresh perspective and is optimistic about its completion.
Collins expressed confidence that…
I had a bittersweet moment today. I watched one of my favorite pieces of healthcare software fade into the sunset. The health system where I spent the majority of my career finally retired the…
Continue ReadingNews
Shares of AI infrastructure companies rise sharply on the White House’s announcement of Stargate, a private sector project in which major technology companies — including OpenAI, SoftBank, and Oracle — will invest up to…
Continue ReadingTop News
Struggling consumer genetic testing company 23andMe considers selling its Lemonaid telehealth business.
23andMe acquired the business in 2021 for $400 million.
23andMe’s entire board resigned last September over differences in the company’s direction. It announced…
Several of my primary care friends got together tonight to drink margaritas. Partly because we’ve all got cabin fever from the weather, and partly to commiserate about our worries about what’s about to happen…
Continue Reading